Tuesday, April 7, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us

Biden administration investing $1.7B into tracking, combating COVID-19 variants

The Biden administration on Friday announced its plans to invest $1.7 billion into tracking and combating COVID-19 variants as new strains make up about half of all infections across the nation.

The administration unveiled its planned distribution of federal funding from the American Rescue Plan directed at assisting the Centers for Disease Control and Prevention (CDC) and state and local governments in detecting and monitoring COVID-19 variants.

“Our ability to spot variants as they emerge and spread is vital, particularly as we aim to get ahead of dangerous variances before they emerge, as they are in the Midwest right now,” Andy Slavitt, senior White House pandemic adviser, said at a Friday COVID-19 response team briefing.

“This investment will give public health officials the chance to react more quickly to prevent and stop the spread,” he added.

Part of the commitment involves designating money to improve genomic sequencing of COVID-19 samples, which helps scientists identify variants and “potentially deadly mutations.”

In February, the U.S. was sequencing about 8,000 samples per week until the administration funneled almost $200 million to increase the pace.

Source: The Hill

Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Videos

Policy Shift in Peptide Regulation

Semaglutide and the Expansion Problem: When One Trial Becomes a Platform

Semaglutide and the Expansion Problem: When One Trial Becomes a Platform

Semaglutide has moved beyond its original indication and now sits at the center of a widening set of clinical questions: cardiovascular risk, kidney disease progression, and even neurodegeneration. The question is no longer whether the drug lowers glucose or reduces weight—it does—but how far those effects extend across systems, and whether evidence from one population can be translated into another without distortion. Large, well-powered trials have produced consistent signals, yet those signals are now being applied in contexts that were...

Read more

Join Our Newsletter!